Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. - sprookjes - yvandenbroek - TriplyDB

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

http://www.wikidata.org/entity/Q30667754

about

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial Toxic optic neuropathies: an updated review Anti-TNF-alpha therapy and systemic vasculitis.The effect of TNFalpha blockade in complicated, refractory Kawasaki disease A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review.Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review.Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis Construction, purification, and characterization of a chimeric TH1 antagonist.Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis.Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study The role of chemokines in Guillain-Barré syndrome.Optic neuritis associated with adalimumab in the treatment of uveitis.Importance of oligodendrocyte protection, BBB breakdown and inflammation for remyelination.Extraintestinal manifestations and complications in inflammatory bowel diseases.Multiple sclerosis susceptibility alleles in African Americans.Potential role of ustekinumab in the treatment of chronic plaque psoriasis Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab.Neurological disorders and inflammatory bowel diseases Tumor necrosis factor inhibitor-associated dermatomyositis Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis.Adverse events in IBD: to stop or continue immune suppressant and biologic treatment A practical approach to monitoring patients on biological agents for the treatment of psoriasis Regulation of progranulin expression in human microglia and proteolysis of progranulin by matrix metalloproteinase-12 (MMP-12).Etanercept in psoriasis: the evidence of its therapeutic impact.Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.Etanercept: effective in the management of hidradenitis suppurativa.Targeting anti-inflammatory treatment can ameliorate injury-induced neuropathic pain.Rheumatoid arthritis: developing pharmacological therapies.Etanercept in the treatment of rheumatoid arthritis Juvenile onset central nervous system folate deficiency and rheumatoid arthritis.TNFalpha: kill or cure for demyelinating disease?The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28 Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

P2860

Q24673716-7878CBB8-C89F-43C4-BD23-907E50D6204C Q24804031-8F5375F7-E9DF-47F0-A2DE-BBB7940BBE3C Q24806367-D5724585-CBCA-4938-AEC8-CC2F56E9AE2F Q26829488-E7D977D4-404C-4F93-A600-B3DA2A53640E Q27025010-20DAA2C7-7F52-400A-A283-F423C174EB90 Q27687590-05E2479C-3057-4F2E-87CE-EFE37AF95FAE Q28199924-B57EDB37-98A9-49DE-945E-22B0E586126D Q28282330-2B7B8C9A-7E2D-459B-A2FC-CE979A947643 Q30047634-3A908F1E-E1FD-4E87-BD53-2D4454160302 Q30574065-7632C8E9-EAD3-4888-80DF-516667714EDE Q30577403-AC67142A-91C7-454C-B77F-2E290D701624 Q30647378-9D1CC6E2-85E9-4B61-99E0-EF9448184C67 Q31165527-A3284481-71CE-4042-93C3-FCCC0732AD71 Q33222422-38ACAEFB-61E2-481B-88EA-CD5FCB5A1EA7 Q33244262-D8B00EFA-09E0-448F-9930-167837AF6119 Q33255239-34B05E14-34BC-4E81-AC52-BEEEF8FEA162 Q33362177-704B37DC-7207-42E1-A745-B480A968EE95 Q33624382-804CACC5-7059-4BC4-9D45-3271D1728109 Q33681462-50531C12-B41C-4B41-A9CC-23370EEDD5DD Q33740931-47D09A98-6133-4D93-A916-294E4F22DD3B Q33866998-3FE9D83C-9E47-4A8B-88DD-5209E7A73141 Q33892035-ECAC9893-E39D-4032-80B4-CD7B1F41DCA8 Q33892602-071FEBAE-0A65-4A05-895D-C9BF5282D57A Q33953687-8C62F452-C7D4-435D-BC9B-5B04402CBE44 Q33958822-3E07D959-DC8A-4D01-BF09-650FC04424AE Q34015824-2B07A9EB-087F-432B-B9C4-5D1C95743C7F Q34023923-60ACDABC-ABCE-4B11-9F05-19A107D5CC0A Q34073191-F7A4065F-2A91-4F0B-AAF1-350F93CE6140 Q34156420-5B86320C-0657-4045-A77C-8ED764AE413B Q34235574-A17E6EBA-9480-43D4-BDCE-3868247D834B Q34450544-ACDA4BE8-71B2-4C21-97AC-9D7CEC7966FA Q34501045-A0D9CAB8-84F4-44DB-9F06-24A3393C2812 Q34502007-966088B4-C8B1-4970-B747-C7026473D4C9 Q34612387-F1AD8AFD-0FD7-4DEB-AB16-8E0CF42750C6 Q34706975-7CEABC41-2DF4-4A0C-97DC-E6F9AC1E4F64 Q34764213-3F10B77D-CC74-4B80-B471-79ADFFFF1275 Q34772547-F7A10A35-3ED8-4BEA-8E50-156F613BACDA Q34859398-D4EA8FE6-2467-4753-9E8F-72267BD04678 Q34897125-D0B7ABC2-1134-4499-93FD-65101AC50D68 Q34962946-7A348A6F-D5F7-46A7-8A75-CD19A8BDD2BD

P2860

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

http://www.wikidata.org/entity/Q30667754

description

2001 nî lūn-bûn

@nan

2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Demyelination occurring during ...... for inflammatory arthritides.

@ast

Demyelination occurring during ...... for inflammatory arthritides.

@en

type

label

Demyelination occurring during ...... for inflammatory arthritides.

@ast

Demyelination occurring during ...... for inflammatory arthritides.

@en

prefLabel

Demyelination occurring during ...... for inflammatory arthritides.

@ast

Demyelination occurring during ...... for inflammatory arthritides.

@en

P1433

Q30667754-321BD1A2-385A-43A8-87C1-CB7AB054909C

P1476

Q30667754-E742506A-FC2C-4203-8114-82DB148B4B8D

P2093

Q30667754-0383F4A0-ECEF-497F-BEE6-AC18CD882FE5

Q30667754-22802559-A72F-40CE-9945-D786234A0E6C

Q30667754-59E4EF18-745D-4C7B-B9B2-EA9E275C054E

Q30667754-952C5D9B-71B0-4A49-966D-6D3F884C7176

Q30667754-9B7799E4-E43D-41EE-837B-8B7C15CBF390

Q30667754-A9816283-ADB4-46C6-A3A9-0FCC53FA95DC

Q30667754-BA9DEB92-D7D1-4751-AE3D-5ED8F4C7EC29

Q30667754-FEE92630-B041-4926-A0E4-7FB1388850C8

P2860

Q30667754-083ABC0D-E813-430C-86AE-2D810A384871

Q30667754-0F329F44-986B-40F7-8B0E-9F0A6441C9E1

Q30667754-1EFAF550-D977-4AF5-8AB4-9075BEEE2A28

Q30667754-1F4997AF-22F6-457C-BCA7-F8340F7EE6D9

Q30667754-2590099A-C8DE-45FB-B831-10DA0B82BA9E

Q30667754-3CF75926-3C49-4E40-AA68-D134A6EDCD3C

Q30667754-475A9136-CC5E-4310-8092-68CD98959851

Q30667754-4F704D2D-7AC5-4DC7-919F-61E3FAF851BD

Q30667754-94C38100-86F4-4B5D-9FF2-DEEBBE7532C4

Q30667754-A542E2C6-3EDE-4D54-A18E-719FD81399F2

P304

Q30667754-71A6F1A6-413C-4E72-94EE-5B876A16E116

P31

Q30667754-24B98DC3-651D-4C72-8ED8-B05E0F9EC9C5

P356

Q30667754-BBB93881-EA8F-459A-9169-FE557292E694

P433

Q30667754-2B67CB4E-2D8C-490F-9A92-BFEC62B54AB0

P478

Q30667754-5C367558-25D3-4123-9117-2A2FD73FDC33

P577

Q30667754-314303A0-7305-4807-ADC7-1A58C334947D

P698

Q30667754-9BF10023-E1DB-47A4-B680-2B544CCEA443

P921

Q30667754-03CFEA15-23FC-4FFD-A716-7D54E9F255E4

P356

1529-0131(200112)44:12%3C2862::AID-ART474%3E3.0.CO;2-W

P1433

Arthritis & Rheumatology

P1476

Demyelination occurring during ...... for inflammatory arthritides.

@en

P2093

Crayton H

http://www.w3.org/2001/XMLSchema#string

Cupps TR

http://www.w3.org/2001/XMLSchema#string

Edwards ET

http://www.w3.org/2001/XMLSchema#string

Mohan N

http://www.w3.org/2001/XMLSchema#string

Oliverio PJ

http://www.w3.org/2001/XMLSchema#string

Richert JR

http://www.w3.org/2001/XMLSchema#string

Sandberg G

http://www.w3.org/2001/XMLSchema#string

Siegel JN

http://www.w3.org/2001/XMLSchema#string

P2860

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Multiple sclerosis

On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.

Approaches for identifying and defining environmentally associated rheumatic disorders.

Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice: models for multiple sclerosis with primary oligodendrogliopathy.

The pathophysiology of tumor necrosis factors.

Tumor necrosis factor identified in multiple sclerosis brain.

A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.

Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors.

P304

2862-2869

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11762947

http://www.w3.org/2001/XMLSchema#string

P921